The International Journal of Tuberculosis and Lung Disease · 2021 · 26 citations · 21 references
PharmacyPharmacokineticsPharmacologyAntimicrobial PharmacotherapyClinical PharmacologyPediatric PharmacotherapyPediatric Drug DosingPediatric PharmacokineticsPediatric PharmacologyPediatric TuberculosisTuberculosis In ChildrenTuberculosis PharmacotherapyMultidrug-resistant OrganismsMultidrug-resistant Tuberculosis TreatmentPediatric Tuberculosis PharmacokineticsPediatric Tuberculosis PharmacotherapyPediatric Tuberculosis TreatmentSafety Profile CharacterizationSingle-arm TrialsTuberculosis Drug Resistance
BACKGROUND: TMC207-C211 (NCT02354014) is a Phase 2, open-label, multicentre, single-arm study to evaluate pharmacokinetics, safety/tolerability, antimycobacterial activity and dose selection of bedaquiline (BDQ) in children (birth to <18 years) with multidrug-resistant-TB (MDR-TB). METHODS: Patients received 24 weeks’ BDQ with an anti-MDR-TB background regimen (BR), followed by 96 weeks of safety follow-up. Results of the primary analysis are presented based on data up to 24 weeks for Cohort 1 (≥12–<18 years; approved adult tablet at the adult dosage) and Cohort 2 (≥5–<12 years; age-appropriate 20 mg tablet at half the adult dosage). RESULTS: Both cohorts had 15 patients, of whom respectively 53% and 40% of Cohort 1 and Cohort 2 children had confirmed/probable pulmonary MDR-TB. Most patients completed 24 weeks´ BDQ/BR treatment (Cohort 1: 93%; Cohort 2: 67%). Geometric mean BDQ area under the curve 168h values of 119,000 ng.h/mL (Cohort 1) and 118,000 ng.h/mL (Cohort 2) at Week 12 were within 60–140% (86,200–201,000 ng.h/mL) of adult target values. Few adverse event (AE) related discontinuations or serious AEs, and no QTcF >460 ms during BDQ/BR treatment or deaths occurred. Of MGIT-evaluable patients, 6/8 (75%) Cohort 1 and 3/3 (100%) Cohort 2 culture converted. CONCLUSION: In children and adolescents aged ≥5–<18 years with MDR-TB, including pre-extensively drug-resistant-TB (pre-XDR-TB) or XDR-TB, 24 weeks of BDQ provided a comparable pharmacokinetic and safety profile to adults.
21
A Diarylquinoline Drug Active on the ATP Synthase of <i>Mycobacterium tuberculosis</i>
Koen Andries, Peter Verhasselt, Jérôme Guillemont et al. · Science · 2004 · 2.2K citations · Full text
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch et al. · New England Journal of Medicine · 2009 · 839 citations · Full text
Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Maria Tarcela Gler, Vija Skripconoka, Epifanio Sànchez-Garavito et al. · New England Journal of Medicine · 2012 · 737 citations · Full text
Andreas H. Diacon, Peter R. Donald, Alexander S. Pym et al. · Antimicrobial Agents and Chemotherapy · 2012 · 380 citations · Full text